Nama's AI scorecard currently rates Tempus AI Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does TEM report earnings?

Tempus AI's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.08.

What is the TEM price target?

The median analyst price target from 18 analysts is $89.50, with a range of $67.00 – $100.00.

Is TEM Shariah compliant?

Nama's AAOIFI-style screen reads Tempus AI as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Tempus AI (TEM)

Healthcare · Health Information Services · NASDAQ

Tempus AI (TEM) is a Healthcare company in the Health Information Services industry. It has a market capitalization of $13.87B and a free-cash-flow yield of -1.9%. Over the most recent reported fiscal year, revenue grew 83.4%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 4.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -2.4% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-27.1%

How far the last close sits under the highest price of the past five years.

Market cap	$13.87B
Trailing P/E	—
Price / book	30.8
Price / sales	9.7
FCF yield	-1.9%
Dividend yield	—
Gross margin	64.0%
Operating margin	-19.8%
Net margin	-17.8%
Revenue growth (YoY)	+83.4%
Revenue growth (3-yr annual)	+58.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	3.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Health Information Services

TEM earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate -$0.08). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	$0.07	-$0.08	+187.5%	$411.54M
Q2 2026	Jul 30, 2026	-$0.04	-$0.15	+73.3%	$382.49M
Q1 2026	May 5, 2026	-$0.13	-$0.20	+35.0%	$348.12M
Q4 2025	Feb 24, 2026	-$0.04	-$0.05	+20.0%	$367.21M

TEM analyst price target

Median target $89.50 from 18 analysts, ranging $67.00 – $100.00.

Health Information Services peers

Ticker	Company	Market cap	P/E
VEEV	Veeva Systems	$49.18B	35.0
BTSG	BrightSpring Health Services	$13.36B	39.3
HNGE	Hinge Health	$9.34B	51.7
HQY	HealthEquity	$8.57B	23.3
TXG	10x Genomics	$7.72B	296.4
DOCS	Doximity	$5.79B	23.7
WAY	Waystar	$5.45B	17.2
HTFL	Heartflow	$4.56B	—

Explore live TEM data on Nama Insights →

Recent Congressional trades

Tempus AI trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Nancy Pelosi	House	Buy	$50,001 - $100,000	Jan 17, 2025

TEM FAQ

Is TEM a buy?: Nama's AI scorecard currently rates Tempus AI Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does TEM report earnings?: Tempus AI's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.08.
What is the TEM price target?: The median analyst price target from 18 analysts is $89.50, with a range of $67.00 – $100.00.
Is TEM Shariah compliant?: Nama's AAOIFI-style screen reads Tempus AI as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.